Key points are not available for this paper at this time.
Another drug class may soon be added to cholesterol-lowering strategies: a chemically modified, small interfering RNA conjugated to the trivalent N-acetylgalactosamine. The siRNAs are oligonucleotide therapeutics, which destroy RNA before a protein is synthesized.
Anastasia Khvorova (Wed,) studied this question.